Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lipocine (LPCN) Accumulated Expenses (2016 - 2025)

Lipocine's Accumulated Expenses history spans 13 years, with the latest figure at $749667.0 for Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 41.99% year-over-year to $749667.0; the TTM value through Sep 2025 reached $749667.0, down 41.99%, while the annual FY2024 figure was $921240.0, 24.39% down from the prior year.
  • Accumulated Expenses reached $749667.0 in Q3 2025 per LPCN's latest filing, up from $685779.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.6 million in Q3 2021 to a low of $567901.0 in Q1 2022.
  • Average Accumulated Expenses over 5 years is $1.1 million, with a median of $1.1 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: soared 103.84% in 2021, then crashed 62.26% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $1.0 million in 2021, then rose by 6.03% to $1.1 million in 2022, then increased by 13.06% to $1.2 million in 2023, then fell by 24.39% to $921240.0 in 2024, then dropped by 18.62% to $749667.0 in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Accumulated Expenses are $749667.0 (Q3 2025), $685779.0 (Q2 2025), and $619410.0 (Q1 2025).